Literature DB >> 25707491

The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer.

Hong Jae Chon1,2, Hye Ryun Kim1,2, Eunah Shin3, Chan Kim1,2, Su Jin Heo1, Choong-Kun Lee1, Jin Kyu Park3, Sung Hoon Noh4, Hyun Cheol Chung1,2,5, Sun Young Rha6,7,8.   

Abstract

BACKGROUND: Rearrangement of ALK is an established driver aberration in lung cancer. Accordingly, this study attempted to determine the frequency and prognostic impact of ALK alterations in patients with surgically resected gastric cancer.
METHODS: The study evaluated ALK alterations in whole tumor sections of 455 curatively resected gastric cancers via immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). Any expression of ALK protein (1+, 2+, 3+ by IHC) was considered as evidence of ALK positivity (ALK+), and the relationship between ALK positivity and clinicopathologic parameters, including survival outcome, was analyzed.
RESULTS: Of the 455 tumors, 38 (8.4 %) were ALK positive, as measured by IHC. Among the ALK+ patients, two displayed break-apart signals of 5 and 11 % on FISH, respectively. The ALK+ patients were younger (57 vs. 61 years; P = 0.02) and more likely to exhibit a signet ring cell component. Moreover, as ALK intensity measured by IHC increased, so did the proportion of signet ring cells in tumors (defined as ≥10 % of tumor cells; P = 0.02). In terms of survival outcome, the ALK+ patients displayed worse disease-free survival (DFS) and overall survival (OS) than the ALK- patients (P = 0.010 for DFS; P = 0.023 for OS). Multivariate analysis demonstrated that ALK+ gastric cancer patients were at an increased risk of recurrence and death after adjustment for sex, age, tumor location, stage, adjuvant chemotherapy, histology, and epidermal growth factor receptor 2 (HER2) positivity (P = 0.04 for DFS; P = 0.02 for OS).
CONCLUSIONS: The findings showed ALK positivity to be an independent negative prognostic factor in surgically resected gastric cancers associated with signet ring cell histology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25707491     DOI: 10.1245/s10434-015-4376-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities.

Authors:  Yosuke Tanaka; Fumiko Chiwaki; Shinya Kojima; Masahito Kawazu; Masayuki Komatsu; Toshihide Ueno; Satoshi Inoue; Shigeki Sekine; Keisuke Matsusaki; Hiromichi Matsushita; Narikazu Boku; Yae Kanai; Yasushi Yatabe; Hiroki Sasaki; Hiroyuki Mano
Journal:  Nat Cancer       Date:  2021-08-16

2.  Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies.

Authors:  Jerold Loh; Yvonne Li En Ang; Amit Jain; Joe Yeong; Raghav Sundar
Journal:  JCO Precis Oncol       Date:  2022-07

3.  ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series.

Authors:  Margherita Ambrosini; Marzia Del Re; Paolo Manca; Andrew Hendifar; Alexander Drilon; Guilherme Harada; Anne Hansen Ree; Samuel Klempner; Gunhild Mari Mælandsmo; Kjersti Flatmark; Hege G Russnes; James M Cleary; Harshabad Singh; Elisa Sottotetti; Antonia Martinetti; Giovanni Randon; Andrea Sartore-Bianchi; Iolanda Capone; Massimo Milione; Maria Di Bartolomeo; Filippo Pietrantonio
Journal:  JCO Precis Oncol       Date:  2022-04

4.  Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia.

Authors:  Hong Jae Chon; Woo Jin Hyung; Chan Kim; Sohee Park; Jie-Hyun Kim; Chan Hyuk Park; Joong Bae Ahn; Hyunki Kim; Hyun Cheol Chung; Sun Young Rha; Sung Hoon Noh; Hei-Cheul Jeung
Journal:  Ann Surg       Date:  2017-05       Impact factor: 12.969

Review 5.  Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives.

Authors:  Antonio Pellino; Erika Riello; Floriana Nappo; Stefano Brignola; Sabina Murgioni; Selma Ahcene Djaballah; Sara Lonardi; Vittorina Zagonel; Massimo Rugge; Fotios Loupakis; Matteo Fassan
Journal:  World J Gastroenterol       Date:  2019-10-14       Impact factor: 5.742

6.  ALK, NUT, and TRK Do Not Play Relevant Roles in Gastric Cancer-Results of an Immunohistochemical Study in a Large Series.

Authors:  Marie-Isabelle Glückstein; Sebastian Dintner; Silvia Miller; Dmytro Vlasenko; Gerhard Schenkirsch; Abbas Agaimy; Bruno Märkl; Bianca Grosser
Journal:  Diagnostics (Basel)       Date:  2022-02-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.